Open Access
Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates
Тип публикации: Journal Article
Дата публикации: 2021-01-01
scimago Q1
wos Q2
БС2
SJR: 1.314
CiteScore: 8.4
Impact factor: 4.5
ISSN: 25164236
PubMed ID:
33554043
Immunology
Immunology and Allergy
Краткое описание
Calicheamicin, the payload of the antibody-drug-conjugates (ADCs) gemtuzumab ozogamicin (Mylotarg®) and inotuzumab ozogamicin (Besponsa®), belongs to the class of enediyne natural products. Since the isolation and structural determination of the neocarzinostatin chromophore in 1985, the enediynes have attracted considerable attention for their value as DNA damaging agents in cancer chemotherapy. Due to their non-discriminatory cytotoxicity towards both cancer and healthy cells, the clinical utilization of enediyne natural products relies on conjugation to an appropriate delivery system, such as an antibody. Here, we review the current landscape of enediynes as payloads of first-generation and next-generation ADCs.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
1
2
|
|
|
Journal of the American Chemical Society
2 публикации, 6.06%
|
|
|
Organic Letters
2 публикации, 6.06%
|
|
|
Journal of Medicinal Chemistry
2 публикации, 6.06%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
2 публикации, 6.06%
|
|
|
Molecules
1 публикация, 3.03%
|
|
|
Pharmaceutics
1 публикация, 3.03%
|
|
|
Antibiotics
1 публикация, 3.03%
|
|
|
Microbial Cell Factories
1 публикация, 3.03%
|
|
|
Biotechnology Journal
1 публикация, 3.03%
|
|
|
Angewandte Chemie
1 публикация, 3.03%
|
|
|
Angewandte Chemie - International Edition
1 публикация, 3.03%
|
|
|
ACS Chemical Biology
1 публикация, 3.03%
|
|
|
Journal of Organic Chemistry
1 публикация, 3.03%
|
|
|
Molecular Pharmaceutics
1 публикация, 3.03%
|
|
|
Journal of Industrial Microbiology and Biotechnology
1 публикация, 3.03%
|
|
|
Helvetica Chimica Acta
1 публикация, 3.03%
|
|
|
Advanced Science
1 публикация, 3.03%
|
|
|
Russian Journal of General Chemistry
1 публикация, 3.03%
|
|
|
Pediatric Neurology
1 публикация, 3.03%
|
|
|
Russian Chemical Reviews
1 публикация, 3.03%
|
|
|
International Journal of Molecular Sciences
1 публикация, 3.03%
|
|
|
European Journal of Medicinal Chemistry
1 публикация, 3.03%
|
|
|
Current Opinion in Chemical Biology
1 публикация, 3.03%
|
|
|
Cancer Immunology, Immunotherapy
1 публикация, 3.03%
|
|
|
Phytotherapy Research
1 публикация, 3.03%
|
|
|
ChemistrySelect
1 публикация, 3.03%
|
|
|
JACS Au
1 публикация, 3.03%
|
|
|
Organic and Biomolecular Chemistry
1 публикация, 3.03%
|
|
|
1
2
|
Издатели
|
2
4
6
8
10
|
|
|
American Chemical Society (ACS)
10 публикаций, 30.3%
|
|
|
Wiley
8 публикаций, 24.24%
|
|
|
MDPI
4 публикации, 12.12%
|
|
|
Springer Nature
3 публикации, 9.09%
|
|
|
Elsevier
3 публикации, 9.09%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 публикации, 6.06%
|
|
|
Pleiades Publishing
1 публикация, 3.03%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 3.03%
|
|
|
Royal Society of Chemistry (RSC)
1 публикация, 3.03%
|
|
|
2
4
6
8
10
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
33
Всего цитирований:
33
Цитирований c 2025:
3
(9.09%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Adhikari A. et al. Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates // Antibody Therapeutics. 2021. Vol. 4. No. 1. pp. 1-15.
ГОСТ со всеми авторами (до 50)
Скопировать
Adhikari A., Shen B., Rader C. P. Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates // Antibody Therapeutics. 2021. Vol. 4. No. 1. pp. 1-15.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1093/abt/tbab001
UR - https://academic.oup.com/abt/article/4/1/1/6089012
TI - Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates
T2 - Antibody Therapeutics
AU - Adhikari, Ajeeth
AU - Shen, Ben
AU - Rader, Christoph P.
PY - 2021
DA - 2021/01/01
PB - Oxford University Press
SP - 1-15
IS - 1
VL - 4
PMID - 33554043
SN - 2516-4236
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2021_Adhikari,
author = {Ajeeth Adhikari and Ben Shen and Christoph P. Rader},
title = {Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates},
journal = {Antibody Therapeutics},
year = {2021},
volume = {4},
publisher = {Oxford University Press},
month = {jan},
url = {https://academic.oup.com/abt/article/4/1/1/6089012},
number = {1},
pages = {1--15},
doi = {10.1093/abt/tbab001}
}
Цитировать
MLA
Скопировать
Adhikari, Ajeeth, et al. “Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates.” Antibody Therapeutics, vol. 4, no. 1, Jan. 2021, pp. 1-15. https://academic.oup.com/abt/article/4/1/1/6089012.